Showing results (271-280 of 297) with videos related to
Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.Nature Communications|November 20, 2020
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.Science Translational Medicine|January 1, 2025
An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroupMark Gower, Ximing Li, Alicia G Aguilar-Navarro, et al.Blood Cancer Discovery|July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease StatesCurtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.Blood Cancer Discovery|May 20, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.Blood Advances|July 11, 2025
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.Biorxiv : the Preprint Server for Biology|November 24, 2025
Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid LeukemiaDarren Lee, Yazan Abu-Shihab, Kate Plas, et al.Blood|May 7, 2025
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic LeukemiaAyalew Tefferi, Saubia Fathima, Maymona Abdelmagid, et al.Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.Pageof 30